Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
Public ClinicalTrials.gov record NCT03203642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Study identification
- NCT ID
- NCT03203642
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Tesevatinib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2017
- Primary completion
- Jan 24, 2022
- Completion
- Jan 24, 2022
- Last update posted
- Feb 5, 2023
2017 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego | La Jolla | California | 92037 | — |
| California Institute for Renal Research | La Mesa | California | 91942 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Yale Nephrology Clinical Research | New Haven | Connecticut | 06520 | — |
| Coastal Nephrology Associates Research Center, LLC | Port Charlotte | Florida | 33952 | — |
| Genesis Clinical Research | Tampa | Florida | 33614 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Rogosin Institute | New York | New York | 10021 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Baylor Scott & White Research Institute | Temple | Texas | 10016 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03203642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03203642 live on ClinicalTrials.gov.